123 related articles for article (PubMed ID: 16483393)
1. Validation of a care and comfort hypertonicity questionnaire.
Nemer McCoy R; Blasco PA; Russman BS; O'Malley JP
Dev Med Child Neurol; 2006 Mar; 48(3):181-7. PubMed ID: 16483393
[TBL] [Abstract][Full Text] [Related]
2. Survival of individuals with cerebral palsy receiving continuous intrathecal baclofen treatment: a matched-cohort study.
Krach LE; Kriel RL; Day SM; Strauss DJ
Dev Med Child Neurol; 2010 Jul; 52(7):672-6. PubMed ID: 19811519
[TBL] [Abstract][Full Text] [Related]
3. Parotid and submandibular botulinum toxin A injections for sialorrhoea in children with cerebral palsy.
Banerjee KJ; Glasson C; O'Flaherty SJ
Dev Med Child Neurol; 2006 Nov; 48(11):883-7. PubMed ID: 17044954
[TBL] [Abstract][Full Text] [Related]
4. Determinants of responsiveness to botulinum toxin, casting, and bracing in the treatment of spastic equinus in children with cerebral palsy.
Yap R; Majnemer A; Benaroch T; Cantin MA
Dev Med Child Neurol; 2010 Feb; 52(2):186-93. PubMed ID: 20412253
[TBL] [Abstract][Full Text] [Related]
5. Botulinum toxin type A injections can be an effective treatment for pain in children with hip spasms and cerebral palsy.
Lundy CT; Doherty GM; Fairhurst CB
Dev Med Child Neurol; 2009 Sep; 51(9):705-10. PubMed ID: 19459910
[TBL] [Abstract][Full Text] [Related]
6. The risk of progression of scoliosis in cerebral palsy patients after intrathecal baclofen therapy.
Senaran H; Shah SA; Presedo A; Dabney KW; Glutting JW; Miller F
Spine (Phila Pa 1976); 2007 Oct; 32(21):2348-54. PubMed ID: 17906577
[TBL] [Abstract][Full Text] [Related]
7. Interobserver agreement of the Gross Motor Function Classification System in an ambulant population of children with cerebral palsy.
McDowell BC; Kerr C; Parkes J
Dev Med Child Neurol; 2007 Jul; 49(7):528-33. PubMed ID: 17593126
[TBL] [Abstract][Full Text] [Related]
8. Effect of intrathecal baclofen on dystonia in children with cerebral palsy and the use of functional scales.
Motta F; Stignani C; Antonello CE
J Pediatr Orthop; 2008 Mar; 28(2):213-7. PubMed ID: 18388717
[TBL] [Abstract][Full Text] [Related]
9. Outcome assessments in children with cerebral palsy, part I: descriptive characteristics of GMFCS Levels I to III.
Oeffinger D; Gorton G; Bagley A; Nicholson D; Barnes D; Calmes J; Abel M; Damiano D; Kryscio R; Rogers S; Tylkowski C
Dev Med Child Neurol; 2007 Mar; 49(3):172-80. PubMed ID: 17355472
[TBL] [Abstract][Full Text] [Related]
10. Intrathecal baclofen in children with spastic cerebral palsy: a double-blind, randomized, placebo-controlled, dose-finding study.
Hoving MA; van Raak EP; Spincemaille GH; Palmans LJ; Sleypen FA; Vles JS;
Dev Med Child Neurol; 2007 Sep; 49(9):654-9. PubMed ID: 17718820
[TBL] [Abstract][Full Text] [Related]
11. Functional outcomes of intramuscular botulinum toxin type a and occupational therapy in the upper limbs of children with cerebral palsy: a randomized controlled trial.
Wallen M; O'Flaherty SJ; Waugh MC
Arch Phys Med Rehabil; 2007 Jan; 88(1):1-10. PubMed ID: 17207668
[TBL] [Abstract][Full Text] [Related]
12. Botulinum toxin type A with oral baclofen versus oral tizanidine: a nonrandomized pilot comparison in patients with cerebral palsy and spastic equinus foot deformity.
Dai AI; Wasay M; Awan S
J Child Neurol; 2008 Dec; 23(12):1464-6. PubMed ID: 19073853
[TBL] [Abstract][Full Text] [Related]
13. Low-dose/high-concentration localized botulinum toxin A improves upper limb movement and function in children with hemiplegic cerebral palsy.
Lowe K; Novak I; Cusick A
Dev Med Child Neurol; 2006 Mar; 48(3):170-5. PubMed ID: 16483391
[TBL] [Abstract][Full Text] [Related]
14. Upper limb function after botulinum toxin A treatment in cerebral palsy: two years follow-up of six cases.
Sätilä H; Kotamäki A; Koivikko M; Autti-Rämö I
Pediatr Rehabil; 2006; 9(3):247-58. PubMed ID: 17050402
[TBL] [Abstract][Full Text] [Related]
15. Walking ability and predictors of performance on the 6-minute walk test in adults with spastic cerebral palsy.
Maanum G; Jahnsen R; Frøslie KF; Larsen KL; Keller A
Dev Med Child Neurol; 2010 Jun; 52(6):e126-32. PubMed ID: 20163429
[TBL] [Abstract][Full Text] [Related]
16. Measuring care and comfort in children with cerebral palsy: the care and comfort caregiver questionnaire.
Hwang M; Kuroda MM; Tann B; Gaebler-Spira DJ
PM R; 2011 Oct; 3(10):912-9. PubMed ID: 21852220
[TBL] [Abstract][Full Text] [Related]
17. Pediatric outcomes data collection instrument scores in ambulatory children with cerebral palsy: an analysis by age groups and severity level.
Barnes D; Linton JL; Sullivan E; Bagley A; Oeffinger D; Abel M; Damiano D; Gorton G; Nicholson D; Romness M; Rogers S; Tylkowski C
J Pediatr Orthop; 2008; 28(1):97-102. PubMed ID: 18157053
[TBL] [Abstract][Full Text] [Related]
18. Initial development and validation of the Caregiver Priorities and Child Health Index of Life with Disabilities (CPCHILD).
Narayanan UG; Fehlings D; Weir S; Knights S; Kiran S; Campbell K
Dev Med Child Neurol; 2006 Oct; 48(10):804-12. PubMed ID: 16978459
[TBL] [Abstract][Full Text] [Related]
19. The natural history of gross motor development in children with cerebral palsy aged 1 to 15 years.
Beckung E; Carlsson G; Carlsdotter S; Uvebrant P
Dev Med Child Neurol; 2007 Oct; 49(10):751-6. PubMed ID: 17880644
[TBL] [Abstract][Full Text] [Related]
20. Upper limb function after intrathecal baclofen treatment in children with cerebral palsy.
Motta F; Stignani C; Antonello CE
J Pediatr Orthop; 2008; 28(1):91-6. PubMed ID: 18157052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
